JP2025509278A5 - - Google Patents

Info

Publication number
JP2025509278A5
JP2025509278A5 JP2024553365A JP2024553365A JP2025509278A5 JP 2025509278 A5 JP2025509278 A5 JP 2025509278A5 JP 2024553365 A JP2024553365 A JP 2024553365A JP 2024553365 A JP2024553365 A JP 2024553365A JP 2025509278 A5 JP2025509278 A5 JP 2025509278A5
Authority
JP
Japan
Application number
JP2024553365A
Other languages
Japanese (ja)
Other versions
JPWO2023170065A5 (https=
JP2025509278A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2023/055751 external-priority patent/WO2023170065A1/en
Publication of JP2025509278A publication Critical patent/JP2025509278A/ja
Publication of JPWO2023170065A5 publication Critical patent/JPWO2023170065A5/ja
Publication of JP2025509278A5 publication Critical patent/JP2025509278A5/ja
Pending legal-status Critical Current

Links

JP2024553365A 2022-03-07 2023-03-07 小細胞肺癌を治療する方法 Pending JP2025509278A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22160556 2022-03-07
EP22160556.1 2022-03-07
PCT/EP2023/055751 WO2023170065A1 (en) 2022-03-07 2023-03-07 Methods of treating small cell lung cancer

Publications (3)

Publication Number Publication Date
JP2025509278A JP2025509278A (ja) 2025-04-11
JPWO2023170065A5 JPWO2023170065A5 (https=) 2026-03-16
JP2025509278A5 true JP2025509278A5 (https=) 2026-03-16

Family

ID=80682926

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024553365A Pending JP2025509278A (ja) 2022-03-07 2023-03-07 小細胞肺癌を治療する方法

Country Status (12)

Country Link
US (1) US20260027117A1 (https=)
EP (1) EP4489756A1 (https=)
JP (1) JP2025509278A (https=)
KR (1) KR20240158972A (https=)
CN (1) CN118843466A (https=)
AR (1) AR128711A1 (https=)
AU (1) AU2023232376A1 (https=)
CA (1) CA3253688A1 (https=)
IL (1) IL315441A (https=)
MX (1) MX2024010900A (https=)
TW (1) TW202337469A (https=)
WO (1) WO2023170065A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025186213A1 (en) * 2024-03-04 2025-09-12 Debiopharm International S.A. Combination of a wee1 inhibitor and a topoisomerase 1 inhibitor
CN118581045A (zh) * 2024-07-29 2024-09-03 云南省肿瘤医院(昆明医科大学第三附属医院) 一株多突变的人小细胞肺癌淋巴结转移原代细胞系及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2608940T3 (es) 2007-06-15 2017-04-17 Msd K.K. Derivado de bicicloanilina
CN104271576A (zh) 2012-02-23 2015-01-07 艾伯维公司 激酶的吡啶并嘧啶酮抑制剂
US10703759B2 (en) 2016-11-16 2020-07-07 Impact Therapeutics, Inc 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-ones
GB201703881D0 (en) * 2017-03-10 2017-04-26 Almac Discovery Ltd Pharmaceutical compounds
WO2022155202A1 (en) 2021-01-13 2022-07-21 Schrödinger, Inc. Fused heterocycles and uses of same
WO2022188802A1 (en) * 2021-03-10 2022-09-15 Impact Therapeutics (Shanghai) , Inc Use of wee1 kinase inhibitors in the treatment of cancer
AU2022287033B2 (en) 2021-06-04 2025-04-17 Aprea Therapeutics, Inc. Pyridopyrimidine derivatives useful as wee1 kinase inhibitors
WO2023093840A1 (en) * 2021-11-26 2023-06-01 Impact Therapeutics (Shanghai) , Inc Use of wee1 kinase inhibitors in the treatment of cancer

Similar Documents

Publication Publication Date Title
BR102023014872A2 (https=)
BR102023012440A2 (https=)
BR102023010976A2 (https=)
BR102023009641A2 (https=)
BR102023008688A2 (https=)
BR102023007252A2 (https=)
BR102023005164A2 (https=)
BR102023001877A2 (https=)
BR102023000289A2 (https=)
BR102022026909A2 (https=)
BR102022023461A2 (https=)
BR202022009269U2 (https=)
BR202022005961U2 (https=)
BR202022001779U2 (https=)
BY13149U (https=)
BY13157U (https=)
CN307050173S (https=)
BY13137U (https=)
BY13140U (https=)
BY13141U (https=)
BY13142U (https=)
BY13143U (https=)
BY13144U (https=)
BY13145U (https=)
CN307050092S (https=)